vanoxerine has been researched along with Parkinson Disease in 2 studies
vanoxerine: structure given in first source
vanoxerine : An N-alkylpiperazine that consists of piperazine bearing 2-bis(4-fluorophenyl)methoxy]ethyl and 3-phenylpropyl groups at positions 1 and 4 respectively. Potent, competitive inhibitor of dopamine uptake (Ki = 1 nM for inhibition of striatal dopamine uptake). Has > 100-fold lower affinity for the noradrenalin and 5-HT uptake carriers. Also a potent sigma ligand (IC50 = 48 nM). Centrally active following systemic administration.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Stopper, H | 1 |
Schupp, N | 1 |
Fazeli, G | 1 |
Dietel, B | 1 |
Queisser, N | 1 |
Walitza, S | 1 |
Gerlach, M | 1 |
Ding, YS | 1 |
Fowler, JS | 1 |
Volkow, ND | 1 |
Gatley, SJ | 1 |
Logan, J | 1 |
Dewey, SL | 1 |
Alexoff, D | 1 |
Fazzini, E | 1 |
Wolf, AP | 1 |
2 other studies available for vanoxerine and Parkinson Disease
Article | Year |
---|---|
Genotoxicity of the neurotransmitter dopamine in vitro.
Topics: Animals; Antioxidants; Apoptosis; Cells, Cultured; Dopamine; Humans; Micronucleus Tests; Mutagenicit | 2009 |
Pharmacokinetics and in vivo specificity of [11C]dl-threo-methylphenidate for the presynaptic dopaminergic neuron.
Topics: Aged; Animals; Chromatography, High Pressure Liquid; Dopamine; Dopamine Uptake Inhibitors; Female; H | 1994 |